Sleep disruption appears to be a core component of Alzheimer's disease (AD) and its pathophysiology. Signature abnormalities of sleep emerge before clinical onset of AD. Moreover, insufficient sleep facilitates accumulation of amyloid-b (Ab), potentially triggering earlier cognitive decline and conversion to AD. Building on such findings, this review has four goals: evaluating (i) associations and plausible mechanisms linking non-rapid-eye-movement (NREM) sleep disruption, Ab, and AD; (ii) a role for NREM sleep disruption as a novel factor linking cortical Ab to impaired hippocampus-dependent memory consolidation; (iii) the potential diagnostic utility of NREM sleep disruption as a new biomarker of AD; and (iv) the possibility of sleep as a new treatment target in aging, affording preventative and therapeutic benefits.
Alzheimer's Disease and the Emerging Interaction with Sleep
AD is one of the largest public health and economic challenges of the 21st century. One in 10 adults over the age of 65 suffer from AD, representing a worldwide epidemic. As a result, there is a pressing need to develop sensitive biomarkers facilitating early detection, and effective treatment interventions [1] . Only by achieving both can the goals of prevention and therapeutic intervention be accomplished [1] . One emerging candidate that may fulfill all of these objectives is sleep. In this review we evaluate evidence linking sleep disturbance with AD and its pathophysiology, especially Ab pathology. We further outline the cognitive consequences of sleep disruption as a novel mechanistic conduit contributing to cognitive decline associated with AD pathophysiology. Finally, we explore the potential of sleep to serve as both a biomarker of AD and as a new therapeutic and preventative strategy for lowering AD risk.
Sleep, Ab, and Alzheimer's Disease
Sleep in Aging A physiological hallmark of advancing age is the decline of sleep, wherein NREM slow wave sleep (SWS) declines are particularly significant [2] . These impairments begin in midlife, and in many older adults age 75 years or older, less than 10% of SWS time remains [2] . Similar reductions in the quality of SWS are observed, measurable in the electroencephalographic (EEG) signature of slow wave activity (SWA; $0.5-4.5 Hz) [3, 4] . These age-related decreases in NREM SWS quantity and quality are paralleled by increasing amounts of time spent awake Trends A bidirectional, causal interaction exists between NREM sleep and Ab pathophysiology that may contribute to Alzheimer's disease (AD) risk and progression.
The disruption of NREM sleep may represent a novel pathway through which cortical Ab impairs hippocampus-dependent memory consolidation.
The disruption of NREM sleep physiology offers potential diagnostic utility in the form of a non-invasive biomarker of Ab pathology, AD risk, and/or AD pathophysiological progression.
Evidence implicates sleep disturbance as a consequence and cause of AD progression; one that is modifiable, offering preventative and therapeutic treatment potential. 
